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Abstract
Higher cyclooxygenase 2 (COX-2) expression is often observed in aggressive colorectal cancers (CRCs). Here, we
attempt to examine the association between COX-2 expression in therapy-refractory CRC, how it affects chemo-
sensitivity, and whether, in primary tumors, it is predictive of clinical outcomes. Our results revealed higher COX-2
expression in chemoresistant CRC cells and tumor xenografts. In vitro, the combination of either aspirin or celecoxib
with 5-fluorouracil (5-FU) was capable of improving chemosensitivity in chemorefractory CRC cells, but a synergistic
effect with 5-FU could only be demonstrated with celecoxib. To examine the potential clinical significance of these
observations, in vivo studies were undertaken, which also showed that the greatest tumor regression was achieved
in chemoresistant xenografts after chemotherapy in combination with celecoxib, but not aspirin. We also noted
that these chemoresistant tumors with higher COX-2 expression had a more aggressive growth rate. Given
the dramatic response to a combination of celecoxib + 5-FU, the possibility that celecoxib may modulate chemo-
sensitivity as a result of its ability to inhibit MDR-1 was examined. In addition, assessment of a tissue microarray
consisting of 130 cases of CRCs revealed that, in humans, higher COX-2 expression was associated with poorer
survival with a 68% increased risk of mortality, indicating that COX-2 expression is a marker of poor clinical outcome.
The findings of this study point to a potential benefit of combining COX-2 inhibitors with current regimens to achieve
better response in the treatment of therapy-refractory CRC and in using COX-2 expression as a prognostic marker to
help identify individuals who would benefit the greatest from closer follow-up and more aggressive therapy.
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Introduction
Aspirin and related products are commonly used to treat inflamma-
tory conditions, and epidemiological studies have also suggested that
long-term treatment with aspirin, nonsteroidal anti-inflammatory
drugs (NSAIDs), or selective cyclooxygenase 2 (COX-2) inhibitors
may reduce the risk of colorectal cancers (CRCs) [1,2] and the devel-
opment of its precursor lesions in sporadic CRC [3,4] and in those
with familial adenomatous polyposis [5]. They decrease prostaglandin
synthesis, which are modulators of cell growth [6], by inhibiting rate-
limiting COX-1 and COX-2 enzymes that catalyze the conversion of
arachidonic acid to prostaglandins and other eicosanoids. COX-1 is
constitutively expressed in many cell types, whereas COX-2 is a pri-
mary response gene that is induced by growth factors and cytokines.
In CRC, increased expression of COX-2 is found in up to 85% of
cases but not in normal colonic epithelium [7,8]. There is also a pro-
gressive overexpression of COX-2 from early adenomas to carcinomas
[9]. Animal studies support a key role of COX-2 in the initiation of
CRC, as treatment of APCΔ716(+/−) mice with a COX-2 inhibitor re-
duces the number of intestinal polyps [10]. Its selective inhibition
results in apoptosis in CRC cells [11,12]. Higher levels of COX-2
expression have also been seen in other types of cancers. For example,
it promotes resistance to apoptosis in non–small cell lung cancer [13],
and its inhibition can diminish growth and induce cell cycle arrest in
hepatocellullar carcinoma cell lines [14]. These observations have led
to studies assessing their cytotoxic effect when used in combination
with conventional chemotherapies, such as 5-fluorouracil (5-FU) or
irinotecan (CPT-11) in CRC cells [15].
Despite convincing in vitro evidence demonstrating an inhibitory
effect of aspirin and related products on CRC cells, clinical studies
assessing the efficacy of COX inhibitors in the treatment of CRC have
met with variable results. Here we examine the efficacy of COX in-
hibition on a specific subset of tumors: chemorefractory CRC. CRC
cells resistant to 5-FU or CPT-11 [16,17] were used to assess the ef-
fect of aspirin, a nonselective COX inhibitor, or celecoxib, a selective
COX-2 inhibitor, in improving chemosensitivity when CRC cells
were exposed in combination with 5-FU or CPT-11 in vitro and
in vivo. Our findings provide a potential biologic explanation for
the negative results of recent clinical trials showing lack of efficacy
of COX inhibitors in CRC. In addition, we also demonstrate that
COX-2 expression is clinically relevant and identifies those individ-
uals with shorter overall survival.
Materials and Methods
Cell Lines
Human CRC cells MIP101 and RKO were maintained in Dulbecco
modified Eagle medium (DMEM) supplemented with 1% penicillin-
streptomycin, 1% kanamycin (Invitrogen, Carlsbad, CA) and 10%new-
born calf serum (NCS) at 37°C and 5% CO2. For resistant cell lines,
media were also supplemented as follows: MIP101 cells resistant to
5-FU (MIP/5-FU), 500 μM 5-FU; CPT-11 (MIP/CPT), 100 μM
CPT-11; RKO cells resistant to 5-FU (RKO/5-FU), 25 μM 5-FU;
CPT-11 (RKO/CPT), 18 μM CPT-11 [16,17]. Chemoresistant cell
lines were generated after incremental exposure to each of the specific
agents (5-FU 10-500 μM,CPT-11 1-50 μM) during a 3-month period,
as previously described, resulting in IC50 at least eight-fold higher than
their sensitive counterparts [16,17]. All cell lines used in these studies
had fewer than 20 passages.
Reverse Transcription–Polymerase Chain Reaction
RNA from CRC cells was extracted using TRIzol reagent (Invitrogen)
24 hours after seeding [16]. Three hundred nanograms of total RNA
was used to generate cDNA (SuperScript III; Invitrogen). Specific pri-
mers for COX-1 (forward, 5′GTTTGGCATGGTGAGTGTTG-3′;
reverse, 5′-AGGCACAGATTCAGGGAATG-3′), COX-2 (forward,
5′CTGTTGCGGAGAAAGGAGTC-3′; reverse, 5′-TCAAACAAG-
CTTTTACAGGTGA-3′), and β-actin [18] were used. Polymerase
chain reaction products were separated on 3.0% agarose gel electro-
phoresis followed by ethidium bromide staining.
Aspirin and Celecoxib—In Vitro Studies
MIP101, MIP/5-FU, MIP/CPT, RKO, RKO/5-FU, and RKO/
CPT cells were treated with aspirin 1.8 mM (in PBS; Sigma, St Louis,
MO) [19,20], celecoxib 30 μM (in 0.1% dimethyl sulfoxide; Pfizer,
New York, NY) [21], or control vehicles. Aspirin concentrations were
based on similar concentrations used in other in vitro studies [19,20,22]
and at pharmacological levels relevant to clinical practice [23]. The
concentration of celecoxib used was also based on previously published
reports [21,24], and these concentrations were clinically relevant given
that serum concentrations of COX-2 inhibitors in patients range from
20 to 100 μM [24,25].
Treated cells were then assessed for the following:
Cell viability. At 24 hours after seeding (∼50% confluence), cells
were treated with 1.8 mM aspirin or 30 μM celecoxib for 48 hours
followed by the addition of 5-μM 5-FU for an additional 48 hours.
Cell viability was assessed by MTT assay. Synergistic effect between
aspirin and celecoxib in combination with chemotherapy was as-
sessed by using the following formula: RI (index) = [(cell survival ob-
served with drug A alone) × (cell survival observed with drug B
alone)] / (cell survival observed with the combination of drug A
and drug B), where an RI ≤ 1.0 represented the absence of syner-
gism or antagonism [26,27].
Clonogenic assay. At 24 hours after seeding, MIP/5-FU cells were
treated with 1.8 mM aspirin or 30 μM celecoxib for 4 hours before the
addition of 250 μM 5-FU (this higher concentration was used because
the IC50 is 10-fold higher in MIP/5-FU cells than the chemosensitive
MIP101 cells). Cells were incubated for a total of 7 days and then
stained with Crystal violet as previously described [16] (n = 4 indepen-
dent experiments).
Cell proliferation. Cells were seeded at equal numbers and 24 hours
later treated with 1.8 to 3.6 mM aspirin or with 25 to 50 μM celecoxib.
Cells were collected and counted for three consecutive days with a
hematocytometer. Each group was counted thrice; averaged readings
were based on three independent experiments.
Caspase 3/7 assay. At 24 hours after seeding, cells were treated with
1.8 mM aspirin or 30 μM celecoxib for 48 hours followed by incuba-
tion with 5 μM 5-FU for 24 hours. Total cell lysates were prepared
using Chaps cell extract buffer (Cell Signaling Technology, Danvers,
MA), and 20 μg of total protein/sample was used in a Caspase-Glo
3/7 Assay (Promega, Fitchburg, WI), as previously described [18].
Relative luminescence units were quantified using Synergy H4 Hybrid
Multi-Mode Microplate Reader (BioTek, Winooski, VT).
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Immunoblot analysis. Forty micrograms of total protein/sample
was loaded from cell lysates prepared from cells that were treated with
1.8 mM aspirin or 30 μM celecoxib for 48 hours followed by exposure
to 5 μM5-FU. Samples were separated on a 10% SDS-PAGE and then
transferred to polyvinylidene fluoride membranes (Bio-Rad, Hercules,
CA) [28]. Immunodetection was performed using antibodies against
COX-2 (1:1000; LabVision, Fremont, CA) and MDR-1 (1:1000;
kindly provided by Dr Victor Ling, British Columbia Cancer Agency)
followed by incubation with the appropriate secondary antibody. All
immunoblots were also probed with antibodies to β-actin (0.32 μg/ml;
Abcam, Cambridge, MA) as a loading control. Proteins were detected
with SuperSignal West Dura (Pierce, Rockford, IL).
Cell cycle analysis. MIP101, MIP/5-FU, and MIP/CPT cells seeded
at 200,000 cells/well in a six-well plate in DMEM (10%, NCS) were
subjected to cell cycle synchronization with double thymidine block
(thymidine 2 mM [Sigma] in DMEM supplemented with 2% NCS)
as previously described [16,28]. After an initial 16 hours of thymidine
block, cells were released in DMEM (10% NCS) for 12 hours, which
was then followed by a second 14-hour thymidine block, and incubated
with 1.8 mM aspirin or 50 μM celecoxib. Cells released from this block
were collected at timed intervals and processed for cell cycle analysis
as previously described [28] and analyzed with Becton Dickinson
FACSCalibur (Franklin Lakes, NJ) (n = 3 independent experiments).
Animal Studies
Tumor xenograft animal models were used to assess the efficacy of the
combination of aspirin or celecoxib and chemotherapy (5-FU or CPT-1)
on tumor progression in vivo. Tumor xenografts of nude mice (6 weeks
old; Taconic, Hudson, NY) were implanted with 1 × 106 (MIP101,
MIP/5-FU, and MIP/CPT) cells into the flanks of each animal. Treat-
ment groups included aspirin ± 5-FU (or CPT-11), celecoxib ± 5-FU (or
CPT-11), 5-FU or CPT-11 alone, and saline (n = 4 to 8 mice per
group). Treatment regimens were initiated once the average tumor size
reached 75 to 100 mm3 as previously described [16]. All studies were
approved by the Animal Care Committee at the University of British
Columbia. Tumors were measured using a handheld caliper (VWR,
Radnor, PA) with concurrent body weight measurements until the com-
pletion of the study. Chemotherapy with 5-FU was provided using a
3-week cycle regimen (six cycles) as previously described [16]. Aspirin
was administered intraperitoneally at 37.9 μg/g of mouse twice a week
(based on an equivalent daily dose of 650 mg of aspirin for a 60-kg per-
son), whereas celecoxib was given at 46.7 μg/g mouse twice weekly
(equivalent to 800 mg daily for a 60-kg person). Control animals
received saline. All mice received care according to standard animal
care protocol and guidelines.
Tissue Microarray of Human CRCs
Paraffin-embedded blocks from 130 clinical samples of CRCs were
constructed (each sample was represented by two cores). Samples
were selected from cases with at least a 5-year follow-up period and
linked to clinicopathologic data. This study was approved by the
ethics board at the University of British Columbia (Canada) and
Ajou School of Medicine (Korea). Immunohistochemical staining
was performed using a COX-2 rabbit polyclonal antibody (LabVision).
Briefly, after deparaffinization, the sections were rehydrated, washed,
and subjected to microwave antigen retrieval in 10 mM citrate buffer,
pH 6.0. The sections then immersed in 3% H2O2 for 15 minutes
to block the endogenous peroxidase activity and next incubated for
30 minutes at room temperature with the anti–COX-2 antibody at
1:100 dilution, followed by detection with Cap-Plus Detection kit
and 3,3′-diaminobenzidine (Zymed, South San Francisco, CA), and
counterstained with Harris hematoxylin. The proportion of tumor cells
showing positive staining was semiquantitatively evaluated as grade 0
(<5% staining), grade 1 (5%-30%), grade 2 (30% to 60%), and grade 3
(>60% staining) by two independent pathologists without having any
knowledge of the clinical outcome.
Statistical Analysis
Statistical difference between groups was calculated and analyzed
using Student’s t test, 2-tailed; significance was defined as P < .05,
using Smith’s Statistical Package. Associations between various factors
were assessed using Fisher exact test. Time to death was used in the
analysis of overall survival. Significance levels, estimates of relative
risk, and 95% confidence intervals were calculated using a proportional
hazard regression model. Survival curves were estimated by the Kaplan-
Meier method [29].
Results
Expression of COX-2 in Sensitive and Resistant CRC Cells
We assessed levels of COX-1 and COX-2 in sensitive MIP101
and RKO CRC cells, and their chemoresistant counterparts (5-FU
chemotherapy-resistant MIP/5-FU and RKO/5-FU cells; and CPT-
11–resistant RKO/CPT cells). We observed higher basal levels of
COX-1 and COX-2 gene expression in chemoresistant cell lines com-
pared with the sensitive cells (Figure 1, A and B). In all cases, COX-2
expression levels decreased after a 48-hour exposure to 1.8 mM aspirin
or 30 μM of celecoxib in MIP101- (Figure 1C) and RKO- (Figure 1D)
chemosensitive cell lines; however, only celecoxib was effective in de-
creasing COX-2 levels in the resistant MIP/5-FU and RKO/5-FU cells.
Aspirin and Celecoxib Reduce Cell Viability and Resensitize
Therapy-Resistant CRC Cells to Chemotherapy In Vitro
An effect of aspirin or celecoxib alone and in combination with 5-FU
in resistant MIP/5-FU cells on cell viability was initially assessed by
clonogenic assays, which demonstrated significantly fewer colonies of
therapy-resistant cells exposed to a combination of 1.8 mM aspirin
or 30 μM celecoxib with 5-FU (Figure 1, E and F). Specifically, only
37.1% ± 7.6% and 44.6% ± 0.7% of colonies remained after treatment
with aspirin (Figure 1Eii) or celecoxib (Figure 1Fii) in combination
with 250 μM 5-FU (P < .01), whereas no significant change was ob-
served after exposure to either agents alone.
Cell viability, as assessed by MTT assays, demonstrated a differential
response between sensitive and chemorefractory CRC cells to either
aspirin or celecoxib: consistently, greater reductions in cell viability was
observed in chemorefractory cells to either aspirin (Figure 2, Aii and
Aiv) or celecoxib (Figure 2, Bii and Biv) in combination with 5-FU over
single 5-FU treatments. Specifically, after a combination of aspirin with
5-FU, a further decrease in cell viability of 18.2% and 24.7% was
observed in resistant MIP/5-FU (Figure 2Aii) and RKO/5-FU cells
(Figure 2Aiv), respectively. Similarly with celecoxib (in combination
with 5-FU, over 5-FU alone), cell viability decreased by an additional
22.0% in the resistant cells (MIP/5-FU— from 104.9% ± 5.8% viable
cells [5-FU only] to 82.0% ± 9.4% [5-FU + celecoxib]; RKO/5-FU—
from 87.9% ± 6.1% [5-FU only] to 65.9% ± 1.7% [5-FU + celecoxib];
P < .001).
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In contrast, in sensitive MIP101 CRC cells, neither aspirin nor
celecoxib (in combination with 5-FU) provided additional reductions
over those seen with single treatments of 5-FU; whereas in RKO
cells, a further decrease in cell viability of 17.7% was only observed
after treatment with aspirin (with 5-FU) but not in combination
with celecoxib.
To evaluate whether aspirin (or celecoxib) works in a synergistic
manner with 5-FU to influence cell viability, the MTT assay results
Figure 1. Higher levels of COX-2 expression are seen in CRC cells. Levels of COX-1 and COX-2 were assessed in sensitive MIP101 and
resistant MIP/5-FU cells (A) or sensitive RKO and resistant RKO/5-FU cells (B) by reverse transcription–polymerase chain reaction. The
effects of aspirin or celecoxib exposures on COX-2 protein expression were also examined in MIP101 and MIP/5-FU (C) and RKO and
RKO/5-FU cells (D) by immunoblot analysis. Clonogenic assays showing MIP/5-FU cells incubated with 1.8 mM aspirin (E) or 30 μM
celecoxib (F) and exposed to 5-FU for 7 days. All results represent mean ± SE (n > 3 independent studies). ASA indicates aspirin;
Cxb, celecoxib.
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were analyzed using RI index, where values greater than 1.0 denote
synergism. The results revealed that a synergistic effect was only noted
following treatment with celecoxib in combination with 5-FU in the
resistant MIP/5-FU and RKO/5-FU cells (Table 1) and not in the
sensitive cells. Interestingly, despite the ability of aspirin (+5-FU) to
potentiate further reductions in cell viability in resistant cells, the
effects of the drugs were not synergistic.
The Combination of Chemotherapy with a COX Inhibitor
Enhances Apoptosis in Chemotherapy-Resistant CRC Cells
The possibility that the effect of either aspirin or celecoxib, together
with 5-FU, in decreasing cell viability in sensitive and resistant cells
could be due, in part, to apoptosis was also examined. MIP101 cells
responded to 5-FU by increasing caspase 3/7 activity by 34.5% ±
5.23% (5-FU alone), and this increased even further by 60.3% ±
5.08% (P < .05) after co-incubation with aspirin (Figure 2Ci). Celecoxib
showed a less, yet significant, increase in caspase 3/7 activity after the
combination therapy in these sensitive cells (Figure 2Cii). In the case of
resistant MIP/5-FU cells, caspase activity did not change significantly
after incubation with 5-FU alone when compared with control untreated
cells; but in combination with aspirin or celecoxib, there was an 18.4% ±
2.3% (P < .05) and 22.8% ± 1.5% (celecoxib + 5-FU) increase in caspase
3/7 activity (Figure 2, Ciii and Civ).
Reduction in Cell Viability Results in Part from Decreased
Cell Proliferation after Aspirin Exposure
We noted that the aspirin (or celecoxib)-mediated reduction in cell
viability in both sensitive MIP101 and resistant MIP/5-FU cells were
due in part to a slower rate of cell proliferation, which translated to an
increase in cell doubling time from 37.3 ± 1.3 to 42.6 ± 4.9 hours (P <
.05) and from 37.3 ± 1.3 to 73.1 ± 7.8 hours (P < .05) for MIP101 cells
exposed to 1.8 and 3.6 mM aspirin, respectively (Figure W1 A). Sim-
ilarly, cell doubling time increased from 58.8 ± 4.4 to 76.3 ± 2.5 hours
(P < .05) and 58.8 ± 4.4 to 74.9 ± 1.6 hours (P < .05) for MIP/5-FU
cells in the presence of 1.8 and 3.6 mM aspirin, respectively. The effect
of celecoxib in diminishing the rate of cell proliferation was most ap-
parent after incubation with 50 μM of celecoxib, with the average cell
doubling time increasing from 26.8 ± 0.35 hours in control MIP101
cells to 33.1 ± 1.87 hours (P < .05) in celecoxib-exposed cells and
Figure 2. Exposure to aspirin and celecoxib decreases cell viability and enhances apoptosis in sensitive and chemoresistant CRC cells
in vitro. (A) MIP101 (i), MIP/5-FU (ii), RKO (iii), and RKO/5-FU (iv) cells were treated with 1.8 mM aspirin (ASA) for 48 hours followed by
exposure to 5 μM 5-FU for an additional 24 hours. (B) MIP101 (i), MIP/5-FU (ii), RKO (iii), and RKO/5-FU (iv) cells were similarly treated
with 30 μM celecoxib (CXB). The percentage of viable cells was calculated based on the OD490 reading of nontreated control cells after
an MTT assay as described in the Materials and Methods section. (C) Caspase 3/7 assay was performed after treatment of MIP101 (i and
ii) and MIP/5-FU (iii and iv) with either 1.8 mM aspirin or 30 μM celecoxib for 48 hours (±5 μM 5-FU for 24 hours). All results represent
mean ± SE (n= 3 independent studies). Statistical significance (“*”= P< .01 between the groups indicated by lines; or “○”= P< .01 in
comparison to the group not treated with either ASA or CXB) is based on 2-tailed pairwise Student’s t test.
Table 1. Assessment of Synergism between COX-2 Inhibitors and Chemotherapy.
Aspirin (mM) 5-FU (5 μM) RI Celecoxib (μM) 5-FU (5 μM) RI
MIP101 cells 1.8 0.99 30 0.87
MIP/5-FU cells 1.8 1.05 30 1.21
RKO cells 1.8 0.93 30 0.97
RKO/5-FU cells 1.8 1.02 30 1.22
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similarly from 47.9 ± 5.3 hours in control MIP/5-FU to 61.8 ± 4.1 hours
(P < .05) after exposure to 50 μM of celecoxib (Figure W1B).
Effect of Aspirin and Celecoxib on Cell Cycle Progression
in Chemotherapy-Resistant Cells
These results demonstrated that the rate of cell proliferation was di-
minished after incubation of sensitive MIP101 and resistant MIP/5-FU
cells to aspirin or celecoxib, and it was associated with an increase in cell
doubling times. Next, we examined the possibility of whether a delay in
cell cycle progression could be a contributing factor. Indeed, a delay to
progress through the G1/S phase was observed because a significantly
greater percentage of cells remained in the G1 phase of the cell cycle after
exposure to 1.8 mM of aspirin in the sensitive MIP101 and resistant
MIP/5-FU or MIP/CPT cells (Figure W2). In MIP101 cells, of the
73.8% of cells that were initially in the G1 phase of the cell cycle, only
29.4% remained after 6 hours. In the presence of aspirin, 37.6% of cells
remained in G1 phase. This delay is evenmore dramatic in resistantMIP/
5-FU and MIP/CPT cells where, in the presence of aspirin, 60.2% and
40.4% of cells failed to progress to the next phase, respectively.
A similar delay in cell cycle progression was observed with celecoxib.
In control MIP 101 cells, 34.5% of the initial 60.3% of MIP101 cells
progressed to the S-phase of the cell cycle, but after exposure to celecoxib,
only 14.8% of the cells entered the S phase, whereas the majority re-
mained in the G1 phase. This delay was also observed inMIP/CPT cells
incubated with celecoxib (Figure W2).
Chemoresistant Tumor Xenografts Treated with
a Combination of Celecoxib with 5-FU Have
Greater Tumor Regression
In vitro, the combination of celecoxib (but not aspirin) with 5-FU
effectively improved sensitivity to 5-FU in 5-FU-chemorefractory CRC
cells in a synergistic manner. To examine the potential clinical signif-
icance of these observations, in vivo studies were undertaken, which
demonstrated that the greatest tumor regression was also achieved in
resistant MIP/5-FU and CPT-resistant MIP/CPT xenografts, but not
in the sensitive MIP101 xenografts, after a combination of chemo-
therapy with celecoxib (Figure 3). In chemosensitive xenografts of
MIP101 cells, 5-FU or CPT-11 in combination with either aspirin
or celecoxib did not influence tumor growth in comparison to either
chemotherapies or COX inhibitors alone (Figure 3, A and B, left
panels). Specifically, in xenografts of sensitive MIP101 cells, the per-
centage change in tumor size was less than 300% of the original tumor
by day 36 of treatment after a combination of chemotherapy with
either aspirin or celecoxib, which were not significantly different in
comparison to any of the agents alone (P > .05).
In xenografts of resistant MIP/5-FU and MIP/CPT cells, however,
treatment with celecoxib in combination with either 5-FU or CPT-
11 resulted in a significantly slower rate of growth by day 21 (in MIP/
5-FU xenografts) and day 28 (inMIP/CPT xenografts) in comparison to
either agents alone. In xenografts of MIP/5-FU cells, tumors remained
less than 100% of the original size after treatment with celecoxib in
combination with 5-FU, whereas tumors treated with either agents
alone had already increased by more than 200% by 21 days of initiating
treatment, P < .05 (Figure 3A, lower right panel ). Celecoxib in combi-
nation with CPT-11 seemed to be even more efficacious because tumor
xenografts of MIP/CPT cells treated with this combination had less
than 40% change in tumor size by day 28 days, whereas all other treat-
ment groups had greater than 200% change in tumor size (P < .05;
Figure 3B, lower right panel).
We also confirmed that resistant MIP/5-FU and MIP/CPT tumor
xenografts had higher COX-2 expression in comparison to xenografts
of sensitive MIP101 cells (Figure 4, Ai and Aii). Interestingly, tumors
with a higher COX-2 expression also experienced a more rapid in-
crease in tumor size (Figure 4Aiii, tumor samples 5-12), in comparison
Figure 3. Celecoxib in combination with chemotherapy induces tumor regression of chemoresistant CRCs in vivo. Mice with MIP101,
MIP/5-FU, and MIP/CPT tumor xenografts were treated with saline (control) or with different drug combinations followed by measure-
ment of tumor size twice per week for a total of 36 days. Percent change in tumor size was calculated with respect to the size of the
tumor before treatment. Results represent data averaged from data obtained from four to eight mice per group. Statistical significance:
*P < .05 in comparison to saline-treated controls; blue arrow, P < .05 in comparison to single treatments (celecoxib, 5-FU or CPT-11).
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to sensitive tumors with a lower COX-2 expression (Figure 4Aiii, tumor
samples 1-4).
Reduction in MDR-1 Expression in Tumor Xenografts
after Exposure to COX inhibitors
Given the dramatic tumor regression observed in therapy-refractory
tumor xenografts to a combination of celecoxib and 5-FU, the possibility
that celecoxib may be modulating chemosensitivity as a result of its ability
to influence multidrug-resistant efflux pumps was examined. In vivo,
lower MDR-1 levels were detected in tumor xenografts of sensitive
MIP101 cells, in comparison to xenografts of resistant MIP/5-FU or
MIP/CPT cells (Figure 4B). In addition, in xenografts ofMIP/CPT cells,
a reduction in MDR-1 levels was noted after exposure to celecoxib alone
or in combination with 5-FU (Figure 4, Ci and Cii). Aspirin (alone or in
combination with 5-FU) was also effective in reducing MDR-1 expres-
sion. However, in these same tumors, COX-2 levels were most effectively
reduced after exposure to celecoxib, whereas no significant decrease in
COX-2 could be observed after treatment with aspirin (Figure 4Ciii).
Interestingly, in vitro, celecoxib in combination with 5-FU seemed
to be more effective in reducing MDR-1 expression in MIP/5-FU cells,
whereas no significant changes were detected after exposure to a com-
bination that included aspirin (Figure 4D).
COX-2 Expression and Clinical Outcomes in CRCs
To assess the clinical significance of higher COX-2 expression in
CRC, we evaluated tissues from 130 individuals and assessed their
clinical outcomes during a 50-month period. On the basis of clinico-
pathologic characteristics, COX-2 expression was significantly higher
in patients older than 65 years (P < .05; Table 2). There did not seem
to be an association between the age of the patient and disease stage
(P = .68), although there was a trend toward a greater likelihood
of developing distant metastasis in these older individuals (P = .053).
Differences in COX-2 expression were independent of disease stage
(P = .59). However, based on multivariate Cox regression analysis,
the mortality risk was significantly higher in individuals with higher
COX-2 expression (grades 1-3) in comparison to those with a low
expression (grade 0; P < .05; Figures 5A and W3), representing a
68% increased risk in mortality (Figure 5B), adjusting for age, sex,
disease stage, and status of distant metastasis.
Discussion
Accumulating evidence from animal and in vitro studies has demon-
strated antitumor properties of aspirin and related NSAIDs against
CRC [30,31]. However, clinical studies have been equivocal in
Figure 4. Expression of COX-2 and MDR-1 in tumor xenografts of sensitive and resistant CRC cells. (A) Basal levels of COX-2 expression
in MIP101 (samples 1-4), MIP/5-FU (samples 5-8), and MIP/CPT (samples 9-12) tumor xenografts treated with saline by immunoblot
analysis (i) and relative levels of COX-2 (ii) normalized to β-actin (densitometry); (iii) bar diagram shows percent increase in tumor size
of these same tumors. (B) MDR-1 expression of MIP101, MIP/5-FU, and MIP/CPT tumor xenografts assessed by immunoblot analysis
(i) and relative levels of MDR-1 (ii) normalized to β-actin. (C) MDR-1 and COX-2 expression inMIP/CPT tumor xenografts after treatment with
indicated drugs, (i) by immunoblot analysis, with relative levels of MDR-1 (ii) and COX-2 (iii) normalized to β-actin. (D) MIP101 and MIP/5-FU
cells were assessed for MDR-1 expression after treatment with different drug combinations in vitro by immunoblot analysis. In all cases,
β-actin was used as a loading control.
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showing a therapeutic advantage of including a COX-2 inhibitor to a
treatment regimen in CRC. In this study, we show that CRC cells
that have become resistant to chemotherapy have significantly higher
levels of COX-2 gene and protein expression than chemosensitive
cells. In addition, we demonstrate the potential therapeutic efficacy
of introducing celecoxib in combination with chemotherapy to over-
come resistance in these therapy-refractory cancer cells in vitro and
in vivo.
Previous studies using “chemotherapy-naive” sensitive cells sup-
port our findings with sensitive CRC cells in that aspirin, and other
nonselective COX inhibitors, suppress tumor growth [32,33]. For
example, using HT-29 cells, the combination of aspirin and 5-FU
in vitro was effective in inhibiting cell proliferation, and increasing
apoptosis by upregulating Bax. Another nonselective NSAID, ibu-
profen, has also been shown to improve the effects of CPT-11, by mod-
ulating tumor angiogenesis [32]. Several studies have also demonstrated
a positive effect of combining specific COX-2 inhibitors with chemo-
therapy 5-FU and/or CPT-11 to promote tumor regression [34,35].
In vitro studies by Chen et al. [15] using HT-29 and SW620 cells
showed a reduction in cell viability only after sequential administration
of a COX-2 inhibitor (etodolac) followed by either 5-FU or SN-38.
In preclinical experimental models, celecoxib decreased the growth of
HT-29 tumor xenografts in a dose-dependent manner, and when ad-
ministered in combination with CPT-11, tumor growth was inhibited
by ∼92% [36]. Another COX-2 inhibitor, rofecoxib, also reduced the
growth of primary MC-26 colon cancer intrasplenic tumors and liver
metastasis when used in combination with either 5-FU or CPT-11
[37]. They also showed that tumors exposed to COX-2 inhibitor had
lower levels of COX-2, cyclin D1, β-catenin, matrix metalloproteinases
1 and 9, and vascular endothelial growth factor expression. Whereas
most preclinical in vitro and in vivo studies have been more consistent
in showing an improvement in chemotherapy response after a com-
bination of either a nonselective or a selective COX-2 inhibitor with
chemotherapy, clinical studies have unfortunately demonstrated vari-
able efficacy [32,36–39]. However, this study helps shed some light
and provides a potential explanation for the inconsistent findings of re-
cent clinical trials assessing the efficacy of combining selective COX-2
inhibitors with various chemotherapies [34,38–41]. We demonstrate
that: (1) in tumors that have become refractory to therapy, the use of
a specific COX-2 inhibitor (celecoxib) dramatically enhances therapeu-
tic response in vivo, in comparison to a nonselective inhibitor (aspirin);
and (2) that celecoxib resensitizes therapy-refractory CRC cells to che-
motherapy (either 5-FU or CPT-11), by enhancing apoptosis in ad-
dition to suppressing MDR-1 expression and tumor growth. These
observations suggest that a selective COX-2 inhibitor is more efficacious
Table 2. Clinicopathologic Characteristics of Cases of CRCs.
Characteristics No. Patients % COX-2–Positive Cases
n %
All cases 131 100.0 92 70.2
Age (years)
<50 22 16.8 13 59.1
>50 98 74.8 79 80.6
Sex
M 65 49.6 37 56.9
F 55 42.0 47 85.5
Stage
I 1 0.8 1 100.0
II 47 35.9 30 63.8
III 72 55.0 52 72.2
IV 8 6.1 8 100.0
Recurrence
None 118 90.1 61 51.7
Local 13 9.9 8 61.5
Distant 38 29.0 28 73.7
Overall survival (years)
>5 4 3.1 2 50.0
<5 126 96.2 87 70.6
Disease-free survival (years)
>5 4 3.1 2 50.0
<5 126 96.2 87 70.6
Figure 5. Association between COX-2 expression in human CRC and prognosis. (A) Kaplan-Meier survival curve based on COX-2 expression
in human CRC. COX-2 = 0 represents grade 0 expression; COX-2 = 1-3, represents grade 1-3 expression. (B) Multivariate COX regression
analysis of clinicopathologic parameters and COX-2 status as prognostic factors in patients with CRCs.
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in promoting tumor regression in therapy-resistant cells not only by
augmenting apoptosis and inhibiting tumor growth via its down-
regulation of COX-2 expression but also by improving drug availability
by lowering MDR-1 levels. Our findings correlate well with the results
of clinical trials where only patients with advanced CRC who had pre-
viously failed chemotherapy were included in the study [38]. Gasparini
et al. [38] were able to demonstrate a positive therapeutic response to
a COX-2 inhibitor when used in combination with chemotherapy.
Similarly, in line with our in vivo results that showed no additional
benefit of treating chemosensitive tumors with COX-2 inhibitors, clini-
cal trials that mostly included chemonaive patients also failed to demon-
strate an objective response with the inclusion of a COX-2 inhibitor in
their chemotherapy regimens [39,40,42,43]. It must be noted that
patients who had prior adjuvant chemotherapy at least 6 months before
enrollment were included in some of these studies with negative results,
but the number of these patient was either not reported [40] or was too
small (16% in the phase 2 study by El-Rayes et al. [39]) to allow for
a subgroup analysis to determine whether COX-2 affected therapeutic
efficacy in this particular subset of patients.
We also observed, not unexpectedly, an up-regulation in multidrug-
resistant efflux pump MDR-1 in tumor xenografts of resistant MIP/
5-FU and MIP/CPT. But interestingly, MDR-1 expression was signif-
icantly lower in tumor xenografts after treatment with a COX inhibitor,
and in vitro, its inhibitory effects were most pronounced with celecoxib
in combination with chemotherapy. As noted above, these observations
help explain the greater efficacy of celecoxib in therapy-resistant CRCs
in that it not only suppresses tumor growth but also downregulates the
expression of the multidrug-resistant efflux pump, thereby resulting in
resensitization of cells to chemotherapy. Recent studies in breast cancer
have also indicated that celecoxib can reduce multidrug-resistant pump
activity [44], with the greatest effect in a mitoxantrone-resistant breast
cancer cell line, MCF7-MX [45] where reductions in mitoxantrone
efflux was observed after treatment with celecoxib. More recently,
MDR-1 expression was shown to be induced by prostaglandin E2
(PGE2), a metabolite of COX-2, in hepatocellular carcinoma [46], which
also helps explain the observation that COX-2 inhibition diminishes
MDR-1 mRNA in thyroid cancer cells [47], CRCs cells [48], and our
own observations.
In this study, exposure to a dose equivalent to taking celecoxib at
400 mg twice daily effectively reduced COX-2 expression in tumor
xenografts. A similar dose has also been shown to inhibit PGE2 syn-
thesis in tumors of patients with pancreatic cancers [49], thereby sup-
porting the pharmacodynamic effects of this dose. It must be noted,
however, that although inhibition of PGE2 was achieved in surgically
resected human pancreatic tumors after only 5 to 15 days of celecoxib
administration in the study by Jimeno et al. [49], there was no evi-
dence of tumor regression in tumor xenografts in mice treated for
28 days with celecoxib alone. The absence of a demonstrable response
to a single agent alone is not surprising and suggests that an approach
that includes a combination chemotherapy cocktail in patients known
to have high intratumoral COX-2 expression may be necessary to
improve response in pancreatic cancers.
In addition to providing evidence that chemotherapy-resistant
CRCs have significantly higher levels of COX-2 expression than
chemosensitive tumors do, we also demonstrated a strong clinical
association between high levels of COX-2 expression in the primary
tumor and subsequent risk of mortality from colon cancer. In sup-
port of our findings, the association between high COX-2 gene ex-
pression with poor survival and response to chemotherapy had also
been previously demonstrated in a smaller study examining 40 patients
[50]. These observations suggest that COX-2 expression may be a
useful prognostic marker and can be used to risk stratify patients
into a group that would benefit not only from more aggressive
follow-up and treatment but also from a combination treatment that
includes a COX-2 inhibitor, such as celecoxib, to help improve
therapeutic response by downregulating MDR-1 and thereby facil-
itate tumor regression.
The results of the current study demonstrate that CRC cells that
are refractory to either 5-FU or CPT-11 undergo greater apoptosis
and have a better response to growth inhibition as a result of exposure
to specific COX-2 inhibitors in vivo. Our findings have important
clinical implications because they suggest that a personalized treat-
ment cocktail that includes a COX-2 inhibitor in selected patients
(those with therapy-refractory tumors with high COX-2 and MDR-1
expression) is more likely to achieve greater tumor regression and an
overall improvement in therapeutic response.
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Figure W1. Exposure to aspirin or celecoxib decreases cell proliferation ofMIP101 andMIP/5-FU cells. (A) The effect of aspirin (▪=0mM,□=1.8mM, and =3.6mMaspirin) or (B) celecoxib (▪=0 μM,□=25 μM, and =50 μMcelecoxib) on cell doubling time ofMIP101 and
MIP/5-FU cells was calculated based on daily cell counts for three consecutive days (n = 3 independent experiments, *P < .05).
Figure W2. Cell cycle analysis of MIP101, MIP/5-FU, andMIP/CPT cells after treatment with 1.8 mM aspirin or 50 μMcelecoxib for 14 hours
and collected after a double thymidine block at various time points, t=0, 3, 6, 9, 12, and 15 hours (▪=G1phase,□=Sphase, =G2 phase).
Figure W3. (A) COX-2 expression in human CRCs. (B) COX-2 expression in relation to disease recurrence. (C) COX-2 expression in re-
lation to stage of disease and survival.
